Skip to NavigationSkip to content

New data for Shionogi’s COVID-19 antiviral show rapid virus clearance

Published on 25/04/22 at 09:29am

Shionogi has announced new results from two late-breaking presentations of S-217622. This is an investigational 3CL protease inhibitor that was studied for once-daily oral administration in mainly vaccinated patients, with no risk factors for severe complications, within five days of COVID-19 symptoms onset.

The results were presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, 23-26 April.

S-217622 demonstrated rapid clearance of the infectious SARS-CoV-2 virus. On day four of treatment (following the third dose), the proportion of patients with positive viral titer decreased by approximately 90% versus placebo. The antiviral shortened infectious virus shedding by 1-2 days versus placebo, and also demonstrated a significant reduction in viral RNA on days 2, 4, 6 and 9, versus placebo.

There was no significant difference in the total score of 12 COVID-19 symptoms between treatment arms, but the antiviral showed improvement in the composite score of five “respiratory and feverish” symptoms.

“These results demonstrate that S-217622 rapidly eliminates SARS-CoV-2 in patients versus placebo, marking its potential, if approved, as an effective treatment option for COVID-19. As infections continue to rise in areas worldwide, it is important we have access to a range of easily administered treatment options to ease the pressures on our healthcare systems,” said Isao Teshirogi, PhD, President and CEO at Shionogi & Co, Ltd. “We look forward to continued study of this antiviral in Phase III trials.”

A separate global Phase III study of S-217622 is now underway – aiming to recruit participants globally to support regulatory filings this year.

Lina Adams

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches